Disc Medicine received a Complete Response Letter from the FDA rejecting its new drug application for bitopertin due to insufficient evidence, causing its stock to fall 22% on February 13, 2026. The Rosen Law Firm is investigating potential securities claims and preparing a class action lawsuit on behalf of shareholders who may have been misled by the company. Investors who purchased Disc Medicine securities might be eligible for compensation without upfront costs through this legal action. Interested parties can join the class action by contacting the Rosen Law Firm.
The Sanofi Foundation has announced a renewed focus on supporting children and young people, especially those with serious illnesses. It plans to invest €15 million annually in programs that improve early diagnosis, care, and social inclusion, partne...
Van Eck Associates Corporation notified a decrease in its voting rights in Endeavour Mining PLC to 6.947% as of June 19, 2026, down from a previous 7.995%. The reduction reflects changes in holdings across various Van Eck ETFs focused on gold miners ...
The Sanofi Foundation is enhancing its focus on supporting children and young people, especially those with serious illnesses, by allocating an annual budget of €15 million. The foundation partners with NGOs and healthcare groups to improve early dia...
Japan's government has allocated $660 million in subsidies to accelerate the development and supply chain of all-solid-state batteries (ASSBs), aiming for commercialization by 2030. This support is part of the Battery Stable Supply Assurance Plan, fo...
The global therapeutic apheresis market, valued at $3.84 billion in 2025, is projected to grow to $8.94 billion by 2035 at a 7.9% CAGR. Growth is fueled by rising chronic and autoimmune diseases, advances in automated apheresis technology, and expand...
